Teva names new board member
Mr Elstein has been a member of Teva’s senior management since 2005. Mr Elstein most recently held the position of executive vice president of global pharmaceutical resources. Prior
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.